E-POSTERS

We kindly remind you that all the abstracts are available on this website.


P001
RISK OF SELF-HARM AND NON-FATAL SUICIDE ATTEMPTS, AND COMPLETED SUICIDE IN PATIENTS WITH PSORIASIS – A POPULATION-BASED COHORT STUDY
A. Egeberg *, P. Hansen, G. Gislason, L. Skov, L. Mallbris

P002

PSORIATIC ARTHRITIS AND PRIMARY SCLEROSING CHOLANGITIS: ROLE OF METHOTREXATE? 
H. Sahel *, S. Khettaoui, A. Belazouz, C. Benmohand, F. Otsmane, B. Bouadjar (Alger, Algeria) 

P003

IXEKIZUMAB PROVIDES IMPROVEMENTS THROUGH 52 WEEKS IN PHYSICAL FUNCTION, QUALITY OF LIFE, AND WORK PRODUCTIVITY IN BIOLOGIC DISEASE-MODIFYING ANTIRHEUMATIC DRUG (BDMARD) NAIVE PATIENTS WITH ACTIVE PSORIATIC ARTHRITIS (PSA)
A. B. Gottlieb*, M. E. Husni, C. L. Shuler, R. Burge, C.-Y. Lin, C. H. Lee, D. D. Gladman (USA) 

P004

THE ACCURACY OF EARP (EARLY ARTHRITIS FOR PSORIATIC PATIENTS) IN SCREENING FOR PSORIATIC ARTHRITIS AMONG ADULT FILIPINO PATIENTS
M. V. L. Llana *, M. Aquino-Villamin, J. E. Sevilleja, B. Carpio, E. Regalado-Morales, A. A. Lapitan-Torres (Philippines) 

P005

MICRORNA BIOMARKERS FOR PSORIASIS ARTHRITIS – EARLY RESULTS
I. W. Paulsen *, H. Munk , B. Grum-Schwensen, G. B. E. Jemec, A. J. Svendsen, J. Troelsen, P. Junker, O. B. Pedersen (Denmark)

P006

ACUTE SERUM AMYLOID A IS PRODUCED BY KERATINOCYTES MAINLY BY IL-17A ACTIVATION AND ITS EXPRESSION COULD CONTRIBUTE TO THE VICIOUS CIRCLE OF PSORIASIS PATHOGENESIS
C. Elodie*, M. Franck, B. François-Xavier, B.-M. Amandine, P. Camille, L. Pierre, G. Gerard, L. Jean-Claude (France)

P007

THE PSORIASIS–ASSOCIATED IL-17A DISTURBS SKIN BARRIER FORMATION IN 3D ORGANOTYPIC SKIN MODELS
C. Pfaff *, Y. Marquardt, K. Czaja, B. Lüscher, J. Baron (Germany)

P008

NOVEL TH17-CELL CYTOKINE MEDIATES THE HIGH ANTI-VIRAL COMPETENCE OF PSORIATIC SKIN
K. Wolk*, K. Witte, E. Witte, M. Raftery, G. Kokolakis, S. Philipp, G. Schönrich, S. Prösch, H.-D. Volk , W. Sterry, R. Sabat (Germany)

P009

METHOTREXATE IN THE TREATMENT OF SEVERE PSORIASIS (PSORIATIC ARTHRITIS, ERYTHRODERMIC PSORIASIS, PUSTULAR PSORIASIS)
B. S. Omar * (Algeria)

P010

RIFAMPICIN – MORE THAN 20-YEAR EXPERIENCE OF ITS USE IN PSORIASIS
I. Grozdev *, N. Tsankov (Bulgaria)

P011

ENHANCED LIVER FIBROSIS TEST (ELF) IN PSORIASIS, PSORIATIC ARTHRITIS AND RHEUMATOID ARTHRITIS PATIENTS: A DAILY PRACTICE COMPARISON WITH PROCOLLAGEN-3 N-TERMINAL PEPTIDE (P3NP).
E. Van Der Voort *, M. wakkee, T. Nijsten (Netherlands)

P012

SCALP PSORIASIS AND BIOLOGIC AGENTS: A COMPARATIVE STUDY FROM A TERTIARY PSORIASIS REFERRAL CENTRE
C. Fotiadou*, E. Lazaridou, E. Sotiriou, Z. Apalla, D. Ioannides (Greece)

P013

PRELIMINARY RESULTS OF A MULTICENTER RETROSPECTIVE STUDY ON THE USE OF BIOLOGICS IN PSORIASIS IN ELDERLY PATIENTS IN FRANCE.
N. Beneton*, E. Mahé, A. Bauchet, G. Chaby, N. Quiles, V. Pallure, A. Khemis, F. Maccari, E. Begon, T. Boyé and Resopso (France)

P014

TREATMENT OF GENERALIZED PUSTULAR PSORIASIS DURING PREGNANCY: A REAL CHALLENGE
A. Zaouak, W. Sassi, H. Hammami, S. Fenniche * (Tunisia)

P015

HYDROGEL FORMULATION OF POLY(LACTIC ACID) (PLA) NANOPARTICLES CONTAINING JAK/STAT INHIBITORS FOR TOPICAL TREATMENT OF PSORIASIS
A.-S. Boisgard*, M. Lamrayah, P. Kirilov, B. Verrier (France)

P016

TURMERIC AS A NEW TOPICAL TREATMENT FOR MILD TO MODERATE PLAQUE PSORIASIS: A PROSPECTIVE, RANDOMIZED HALF-BODY COMPARATIVE STUDY
P. Mansouri*, M. Rajabi, G. Sarafian, R. Chalangari, K. Martits-Chalangari (USA)

P017

LIPOSPHERE MEDIATED CODELIVERY OF TACROLIMUS AND CURCUMIN FOR TREATMENT OF PSORIASIS
A. Jain*, S. Doppalapudi, W. Khan (India)

P018

LOW DOSE CYCLOSPORINE HAS AN EFFECT OF IMMUNOMODULATION, NOT IMMUNOSUPPRESSION, IN KOREAN PATIENTS WITH PSORIASIS
J. H. Choi, E.-J. Shin, M. K. Shin, N.-I. Kim (Republic of Korea)

P019

HEPATOTOXICITY WITH METHOTREXATE THROUGH 25 YEARS PHARMACOVIGILANCE SURVEY
M. alkathiri *, S. youssef, M. karray, F. alaoui, N. abdelhedi, K. jaber, R. dhaoui, N. doss (Tunisia)  

P020

CURRENT STATUS OF OBSERVATIONS OF MALIGNANCIES IN THE PSORIASIS LONGITUDINAL ASSESSMENT AND REGISTRY (PSOLAR) STUDY
D. Fiorentino*, M. Lebwohl , V. Ho , R. Langley , K. Goyal, S. Fakharzadeh , S. Calabro , W. Langholff (USA)

P021

BIOLOGIC THERAPY AND INTRODUCTION OF BIOSIMILARS FOR SEVERE PSORIASIS IN KAUNAS, LITHUANIA
I. Subotinaite*, I. Petraityte, S. Valiukeviciene (Lithuania)

P022

PSORIATIC NAILS: A PROSPECTIVE CLINICAL STUDY
F. Jendoubi*, K. Jaber, F. Rabhi , S. Youssef , M. R. Dhaoui , S. Gargouri , N. Doss (Tunisia)

P023

FACTORS ASSOCIATED WITH SUCCESSFUL SWITCHING BETWEEN BIOLOGIC THERAPIES FOR THE TREATMENT OF PSORIASIS IN DAILY DERMATOLOGICAL REAL-LIFE PRACTICE: THE RESOSWITCH STUDY
F. Dabouz , A. Khemis , M. Lahfa , F. Maccari , G. Chaby , N. Beneton , T. Boye , E. Esteve , E. Mahé , E. Begon , C. Pauwels , P. Bernard , Z. Reguiai * and RESOPSO (France)

P024

CHARACTERIZATION OF THE SKIN TH17 TRANSCRIPTIONAL PROFILES IN PSORIATIC PATIENTS UNDER ADALIMUMAB BIOTHERAPY
F. Morel *, E. Couderc , A. Buffière-Morgado , A. Delwail , L. Favot , J.-F. Jégou , G. Guillet , J.-C. Lecron (France)

P025

EFFICACY AND SAFETY OF IXEKIZUMAB OVER FOUR YEARS OF OPEN-LABEL TREATMENT IN A PHASE 2 STUDY IN CHRONIC PLAQUE PSORIASIS
K. Gordon*, C.  Leonardi , A. Blauvelt , C. Zachariae , G. Cameron , M. McKean-Matthews, T.  Ridenour , M. Lebwohl (USA)

P026

EFFICACY AND SAFETY OF IXEKIZUMAB IN PSORIASIS PATIENTS WHO FAILED TO REACH PASI 75 ON ETANERCEPT: SUBANALYSIS OF UNCOVER-3
A. Blauvelt , K. Papp *, L. Puig , Y. Dutronc , L. Kerr , L. Mallbris , D. Ilo, J. Weisman, M. Augustin (Germany)

P027

CODED UNANI FORMULATIONS (UNIM 401 SYSTEMICALLY AND UNIM 403 TOPICALLY) AND PUVASOL IN CHRONIC PLAQUE PSORIASIS: NON-INFERIORITY RANDOMIZED CONTROLLED CLINICAL TRIAL
N. KHANNA *, T. NAZLI , K. M. SIDDIQUI, M. KALAIVANI , R. U. RAHMAN (India)

P028

POSITIVELY AND NEGATIVELY CHARGED LIPOSOMES AS CARRIERS FOR TRANSDERMAL DELIVERY OF PSORALEN: IN VITRO AND IN VIVO EVALUATION
S. Doppalapudi *, A. Jain, W. Khan (India)

P029

« THÉO ET LES PSORIANAUTES » (THÉO AND THE PSORIANAUTES) A SERIOUS GAME DEVELOPED FOR CHILDREN WITH PSORIASIS
M. Aubin, N. Piérard , E. Mahé (France)

P030

MANAGEMENT OF CHILDHOOD PSORIASIS IN FRANCE. A NATIONAL SURVEY AMONG GENERAL PRACTITIONERS, PEDIATRICIANS, AND DERMATOLOGISTS
E. Mahé *, A.-C. Bursztejn, A. Phan , F. Corgibet , A. Beauchet , M.-L. Sigal (France)

P031

PRE- AND NEONATAL RISK FACTORS FOR DEVELOPMENT OF PSORIASIS
A. Egeberg *, L. Mallbris , G. Gislason , L. Skov (Denmark)

P032

PSYCHOMETRIC EVALUATION OF THE SELF-ASSESSMENT OF PSORIASIS SYMPTOMS (SAPS)-CLINICAL TRIAL AND THE SAPS-REAL WORLD PATIENT REPORTED OUTCOMES
A. Armstrong*, B. Banderas , M. Sundaram , C. Foley , F. Ojo , A. L. Shields (USA)

P033

EPIDEMIOLOGICAL DATA IN CHILDHOOD PSORIASIS
I. Dencheva , I. Botev *, L. Miteva (Bulgaria)

P034

THE ROLE OF CLINICIANS, PATIENTS AND SOCIAL FACTORS IN POOR ADHERENCE: CREATING NEW UNDERSTANDING AND CONSULTATION SKILLS TO INCREASE ADHERENCE AND SELF-MANAGEMENT PSORIASIS PATIENTS
C. Bundy * (United Kindgom)

P035

THE NAIL PSORIASIS SEVERITY INDEX (NAPSI) 13 YEARS LATER:  VALIDATION OF AN INSTRUMENT TO ASSESS PSORIATIC NAIL INVOLVEMENT
J. Jefferson, R. Manhart , J. Moore, R. Scher , P. Rich* (USA)

P036

QUALITY OF LIFE AND COMORBIDITIES IN PALMOPLANTAR PUSTULOSIS – A CROSS SECTIONAL STUDY ON 102 PATIENTS
H. Trattner *, I. Steiner , A. Tanew (Austria)

P037
ABSOLUTE PASI AS A MARKER OF EFFECTIVENESS IN LONG-TERM USTEKINUMAB THERAPY AFTER 36 MONTHS
Eiris N.*, Varas Meis E., Alonso Alonso T., Delgado Vicente S., Rodríguez Prieto M. A. (León, Spain)

P038
PASI 75 OR PASI 90? SUGGESTIONS BASED ON DEAD SEA CLIMATOTHERAPY RESULTS

Harari M.* (Ein Bokek, Israel)

P039

SAFETY OF ADALIMUMAB IN PEDIATRIC PATIENTS WITH PSORIASIS, POLYARTICULAR JUVENILE IDIOPATHIC ARTHRITIS, ENTHESITIS-RELATED ARTHRITIS, AND CROHN’S DISEASE
Seyger M.*, Horneff G., Arikan D., Kalabic J., Anderson J., Lazar A., Williams D., Wang C., Tarzynski-Potempa R., Hyams J. (Nijmegen, Netherlands)

P040

CLINICAL ANALYSIS OF ELEVEN JAPANESE PATIENTS WITH CHILDHOOD-ONSET PSORIATIC ARTHRITIS
Wada M.*, Akioka S., Ouchi K., Katoh N. (Kyoto, Japan)

P041
OVERWEIGHT AND CHILDHOOD PSORIASIS: A TUNISIAN PROSPECTIVE STUDY

Rabhi F.*, jaber K., jendoubi F., youssef S., Dhaoui M. R., mrabet A., doss N. (Tunis, Tunisia)

P042
CHILDHOOD PSORIASIS THROUGH A SERIES OF 78 CASES

Nakouri I.*, Jaber K., Litaiem N., Youssef S., Dhaoui M. R., Doss N. (Tunis, Tunisia)

P043
TREATMENT OF SEVERE PEDIATRIC PSORIASIS BY METHOTREXATE: REPORT OF 6 CASES

Nakouri I.*, Jaber K., Litaiem N., Youssef S., Dhaoui M. R., Doss N. (Tunis, Tunisia)

P044
INFANTILE ANNULAR PUSTULAR PSORIASIS: A CASE REPORT

Nakouri I.*, Jaber K., Litaiem N., Youssef S., Dhaoui M. R., Doss N. (Tunis, Tunisia)

P045
SUCCESSFUL TREATMENT OF GENERALIZED PUSTULAR PSORIASIS IN A PREGNANT CHINESE WOMAN WITH SINGLE-DOSE INFLIXIMAB

Gao J., Liao W., Wang L., Hao J., Wang G.* (Xi'an, China)

P046

SEVERE FORMS OF PSORIASIS IN CHILDREN
Zaouak A., Jrad M., Hammami H., Fenniche S.* (Tunis, Tunisia)

P047

CHILDHOOD PSORIASIS AND DIABETES – A SNAPSHOT
Grozdev I.* (Brussels, Belgium)

P048

EPIDEMIOLOGICAL, CLINICAL FEATURES AND TREATMENT OF CHILDHOOD PSORIASIS IN TUNISIA
Bacha T., Zaouak A., Hammami H., Midassi O., Fenniche S.* (Tunis, Tunisia)

P049

PSORIASIS, INSULIN RESISTANCE AND ACANTHOSIS NIGRICANS IN TWO CASES
Sahel H.*, Otsmane F., Bouadjar B. (Alger, Algeria)

P050

CHILDHOOD PSORIASIS: EPIDEMIOCLINICAL ASPECTS
Ouafa H.*, Amal S. (Marrakesh, Morocco)

P051
EFFECT OF CONCOMITANT CONVENTIONAL DISEASE-MODIFYING ANTIRHEUMATIC DRUG (CDMARDS) ON SAFETY AND EFFICACY OF IXEKIZUMAB IN BIOLOGIC DMARD (BDMARD) NAIVE PATIENTS WITH ACTIVE PSORIATIC ARTHRITIS (PSA)
Coates L. C., Gottlieb A. B.*, Shuler C. L., Lin C.-Y., Samanta S., Moriarty S. R., Lee C. H., Mease P. J. (Boston, United States)

P052

52-WEEK EFFICACY AND SAFETY RESULTS FROM SPIRIT-P1: A PHASE 3 STUDY OF IXEKIZUMAB IN PATIENTS WITH ACTIVE PSORIATIC ARTHRITIS
Mease P.*, Okada M., Kishimoto M., Shuler C., Carlier H., Lin C.-Y., Mou J., Moriarty S., Lee C., Gladman D. (Seattle, United States)

P053

PSORIATIC ARTHRITIS THROUGH A SERIES OF 25 CASES
Nakouri I.*, Youssef S., Metoui L., Jendoubi F., Othmani S., Doss N. (Tunis, Tunisia)

P054

PSORIATIC ARTHRITIS REVEALED BY ANTERIOR UVEITIS
Zaouak A., Jrad  M., Hammami H., Midassi O., Fenniche S.* (Tunis, Tunisia)

P055

PUSTULAR PSORIASIS AND PSORIATIC ARTHRITIS: 13 CASES REPORTED IN A MULTIDISCIPLINANARY UNIT
Pérez-Barrio S.*, García-Vivar M. L., Galíndez-Agirregoikoa E., Blanco J., Yague J. A., Blanch L., Izu R. (Bilbao, Spain)

P056

SCREENING OF PSORIATIC ARTHRITIS IN SLOVAKIA
Urbancek S.*, Sutka R., Kmecova Z., Salkovska J., Vano I., Rovensky J. (Banska Bystrica, Slovakia)

P057

EARLY DETECTION OF PSORIATIC ARTHRITIS IN EGYPTIAN  PATIENTS
Hamdy El Sayed M.*, Asaad M., Mohammad  H. (Cairo, Egypt)

P058

THE ASSOCIATION BETWEEN PASI AND CARDIOVASCULAR RISK FACTOR IN KOREAN PSORIASIS PATIENTS
Kim K., Lee M., Jung J.* (Gyeonggi-do, Korea, Republic Of)

P059

BIOLOGIC THERAPY FOR PSORIASIS IS NOT ASSOCIATED WITH MACE IN REAL WORLD CLINICAL PRACTICE: A CANADIAN MULTICENTER RETROSPECTIVE STUDY
Qiang J., Kim W., Yeung J.* (Toronto, Canada)

P060

CARDIOVASCULAR RISKS OF KOREAN PSORIASIS PATIENTS BY ASSESSING ARTERIAL STIFFNESS
Ahn K. J.*, Park H. J., Choi B. G., Kim M. J., Lee Y. W., Choe Y. B. (Seoul, Korea, Republic Of)

P061

MELKERSSON-ROSENTHAL SYNDROME AND PSORIASIS: AN ASSOCIATION BEYOND COINCIDENCY ?
Incel Uysal P.*, Yalcin B., Kayacetin S., Bozdogan O. (Ankara, Turkey)

P062

ASSOCIATION OF HEPATITIS B VIRUS INFECTION IN PSORIASIS
Youn J. I.*, SUH H. Y., KIM  H. L., KIM K. H., AHN J. Y., PARK M. Y., KIM K. J. (Seoul, Korea, Republic Of)

P063

SAFETY AND EFFICACY OF BIOLOGIC THERAPIES IN PSORIATIC PATIENTS WITH ALCOHOLIC CIRRHOSIS: A FRENCH RETROSPECTIVE STUDY OF 23 CASES
Begon E.*, Beneton N., Poiraud C., Droitcourt C., Jacobzone C., Vermersch Langlin A., Descamps V., Perrot J. L., Khemis A., Pallure V., Fougerousse A. C., Sigal M. L., Goujon C., Avenel M., Schmutz J. L., Reguiai Z. et GEM RESOPSO (Pontoise, France)

P064

QUANTIFERON-TB GOLD TEST IN KOREAN PATIENTS WITH PSORIASIS
Park H. J.*, Choe Y. B., Choi B. G., Kim M. J., Lee Y. W., Ahn K. J. (Goyang, Korea, Republic Of)

P065

MALIGNANT MELANOMA ARISING IN A PATIENT TREATED WITH TUMOUR NECROSIS FACTOR (TNF) – A INHIBITORS: A CASE REPORT AND A SHORT REVIEW OF THE LITERATURE.
Matoula T., Kostopoulos N., Panagakis P.* (Athens, Greece)

P066

RELATIONSHIP ACTIVITY INDEX PSORIASIS AND GLYCEMIC CONTROL IN PATIENTS WITH DIABETES MELLITUS AND PSORIASIS.  DR. R. GASCA, DR. A. LÓPEZ TELLO, DR H. MATEOS
Lopeztello A. L. L., GASCA R.* (toluca, Mexico)

P067

CONCOMITANCE OF PSORIASIS AND ATOPIC DERMATITIS: PSORIASIFORM DERMATITIS OR ECZEMATOUS PSORIASIS?
Kim D. H.*, Yoon M. S., Lee H. J., Hyun D. J., Seo S. R., Jeong I. J. (Seongnam, Korea, Republic Of)

P068

INCIDENCE OF CROHN’S DISEASE AND ULCERATIVE COLITIS IN ADULT PATIENTS WITH PSORIASIS VERSUS THE GENERAL ADULT POPULATION
Scosyrev E., Primatesta P.* (Basel, Switzerland)

P069

SHORT AND LONG-TERM RESPONSE AND REMISSION OF DEPRESSIVE SYMPTOMS IN PSORIASIS PATIENTS TREATED CONTINUOUSLY WITH IXEKIZUMAB IN UNCOVER-3
Griffiths C. E.*, Fava M., Mrowietz U., Miller A., Russell J., Ball S., Zhang L., Acharya N., Rapaport M. (Manchester, United Kingdom)

P070

THE IMPACT OF PSORIASIS ON SUBCLINICAL ATHEROSCLEROSIS ASSESSED BY CAROTID INTIMA-MEDIA THICKNESS USING THE ULTRASOUND TECHNIQUE: A LARGE COHORT STUDY
Sabbag C. Y.*, Bittencourt M., Staniak H., Santos I., Sharovsky R., Goulart A., Bensenõr I., Lotufo P. (São Paulo, Brazil)

P071

REDUCED CORONARY ARTERY DISEASE PROGRESSION IN PATIENTS WITH SEVERE PSORIASIS TREATED WITH BIOLOGIC AGENTS
Hjuler K. F.*, Bøttcher M., Vestergaard C., Bøtker H. E., Kragballe K., Iversen L. (DK-8000 Aarhus, Denmark)

P072

AN AUTOMATIC CONVERSATIONAL DEVICE TO ESTIMATE THE INCIDENCE OF OBESITY IN PSORIASIS.
De La Brassinne M.*, Vanhooteghem O. (Liège, Belgium)

P073

NEPHROPATHY IN PATIENTS WITH PSORIASIS
KREIMER J.*, KOGAN N., GUSIS S., VEIRA R. (Buenos Aires, Argentina)

P074

PSORIASIS IS THE INDEPENDENT FACTOR FOR EARLY ATHEROSCLEROSIS: A PROSPECTIVE STUDY OF CARDIOMETABOLIC RISK PROFILE
Dinic M.*, Hajdukovic Z., Mijuskovic M., Djuric P., Kandolf Sekulovic L. (Belgrade, Serbia)

P075

INVESTIGATION ABOUT COMORBIDITIES OF KOREAN PSORIASIS PATIENTS
Lee K.*, Yang J., Yoo J., Chang G. T. (Seoul, Korea, Republic Of)

P076

PREVALENCE OF INFLAMMATORY BOWEL DISEASE IN FUKUOKA UNIVERISTY PSORIASIS REGISTRY.
Imafuku S.*, Ito K., Naito R., Masaki-Tatematsu S., Ihara H., Ohga Y., Shibayama Y., Suzuki Y., Koga M., Tsuruta N. (Fukuoka, Japan)

P077

LIPIDOMICS ANALYSIS METABOLITE DIFFERENCES IN PSORIASIS
Chen X., Peng C.*, Jia X., Su J., Zhao S. (Changsha City, Hunan Province, China)

P078

PSORIASIS AND METABOLIC SYNDROME: A PROSPECTIVE STUDY OF A DEPARTMENT OF DERMATOLOGY IN ALGIERS.
Sahel H.*, Otsmane F., Bouadjar B. (Algiers, Algeria)

P079

IMPACT OF BODY MASS INDEX ON PSORIASIS IN TUNISIAN PATIENTS
Karray M.*, Youssef S., Alkathiri M., Alaoui F., Abdelhedi N., Jaber K., Dhaoui R., Doss N. (Tunis, Tunisia)

P080

GENDER-RELATED DIFFERENCES IN PREVALENCE OF CARDIOVASCULAR COMORBIDITY IN YOUNG PATIENTS WITH SEVERE PLAQUE PSORIASIS: A HOSPITAL-BASED STUDY.
Batkaeva N., Korotaeva T.*, Batkaev E. (Moscow, Russian Federation)

P081

ENDOTHELIAL PLASMA LEVELS ARE NOT RELATED TO THE SEVERITY OF PSORIASIS
Tiran B., Čeović R., Stanimirović A.*, Krnjević Pezić G., Kovacevic M., Kostović K., Tomić Babić L., Frank S. (Zagreb, Croatia)

P082

A STUDY ON PREVALENCE OF NON ALCOHOLIC FATTY LIVER DISEASE(NAFLD) IN MODERATE TO SEVERE PSORIASIS AND ITS RELATION TO ABDOMINAL OBESITY AND INSULIN RESISTANCE.
Basireddy B., alur s K.*, chagam U. R. (Hyderabad, India)

P083

PLAQUE PSORIASIS IS ASSOCIATED WITH SUBCLINICAL ATHEROSCLEROSIS: A CROSS-SECTIONAL STUDY IN CHINA
Xu F., Wen X., Yan W., Wang L., Zhang R., Li M., Li W.* (Chengdu, China)

P084

TREATMENT OPTIONS FOR A PATIENT WITH MODERATE-SEVERE PSORIASIS VULGARIS AND MULTIPLE COMORBIDITIES- A CASE PRESENTATION
Manole I.* (Bucharest, Romania)

P085

RENAL INSUFFICIENCY DUE TO SECONDARY AMYLOIDOSIS  – YET ANOTHER COMORBIDITY OF PSORIASIS?
Maronna A., Sticherling M.* (Erlangen, Germany)

P086

LIPID METABOLISM IN PSORIATIC PATIENTS
Georgescu M.*, Tilea A. M., Tiplica G. S. (BUCHAREST, Romania)

P087

THE RELATIONSHIP BETWEEN DEMOGRAPHIC AND CLINICAL FACTORS, AND QUALITY OF LIFE IN PATIENTS WITH PSORIASIS
Petraskiene R.*, Sukiene A., Valiukeviciene S., Macijauskiene J. (Kaunas, Lithuania)

P088

SOCIOECONOMIC FACTORS ASSOCIATED WITH USING SYSTEMIC CORTICOSTEROIDS IN PSORIASIS PATIENTS
Eun S. J., Jang S., Lee J. Y., Do Y. K., Jo S. J.* (Seoul, Korea, Republic Of)

P089

PSORIASIS A REASON OF INAPTITUDE TO MILITARY SERVICE
Abdelhedi N.*, youssef S., khzouri T., alkathiri M., alaoui F., karray M., jaber K., dhaoui R., doss N. (tunis, Tunisia)

P090

IMPACT OF EPIDEMIOCLINICAL CHARACTERISTICS OF PSORIASIS ON THE QUALITY OF LIFE OF PATIENTS
Alkathiri M.*, youssef S., karray M., alaoui F., abdelhedi N., jaber K., dhaoui R., doss N. (tunis, Tunisia) 

P091

SYMPTOMS OF SYMPTOMS OF ANXIETY AND DEPRESSION AMONG PATIENTS WITH PSORIASIS EVALUATED DURING THE DAY OF DETECTION OF PSORIASIS IN MEXICO AMONG PATIENTS WITH PSORIASIS EVALUATED DURING THE DAY OF DETECTION OF PSORIASIS IN MEXICO
Garcia Hidalgo L.*, Vargas Martinez M. D. L. A., Aguilar Silva J., Trejo Terreros V., Guzman Resendiz M. (Mexico City, Mexico)

P092

IGE AND FCΕRI ARE HIGHLY EXPRESSED ON INNATE CELLS IN PSORIASIS
Yan K.* (shanghai, China)

P093

A PRELIMINARY STUDY OF NEW SINGLE NUCLEOTIDE POLYMORPHISM FOR PSORIASIS IN THE KOREAN POPULATION
Choe Y. B.*, Park H. J., Kim S. Y., Choi B. G., Kim M. J., Lee Y. W., Ahn K. J. (Seoul, Korea, Republic Of)

P094

PLASMACYTOID DENDRITIC CELLS IN PSORIASIS AND PITYRIASIS RUBRA PILARIS: FURTHER EVIDENCE OF LINKED PATHOGENESIS
Abbas O.*, Kurban M. (Beirut, Lebanon)

P095

ARE THE INTERLEUKIN-15 AND -22 A NEW PATHOGENIC FACTOR IN PUSTULAR PALMOPLANTAR PSORIASIS?
Lesiak A.*, Bednarski I., Narbutt J. (Lodz, Poland)

P096

THE STUDY ON THE REGULATION OF CALCITONIN GENE-RELATED PEPTIDE ON CHEMOTACTIC OF ENDOTHELIAL CELLS AND SIGNAL PATHWAY IN PSORIASIS
He Y.*, Tan Y. (Beijing, China)

P097

IDENTIFICATION OF HELICOBACTER PYLORI BY UREA BREATH TEST AND SEROLOGY IN THE PATIENTS WITH PSORIASIS
Balcı D. D.*, Peker Yalcın H., Özer B., Duran N., İnan M. U., Yenin J. Z. (İzmir, Turkey)

P098

ASSESSMENT OF PRURITUS ACCORDING TO CLINICAL PHENOTYPE IN PATIENTS WITH PSORIASIS
Park S.-M.,  Park C.-J., Ko H.-C., Kim M.-B., Kim B.-S.* (Busan, Korea, Republic Of)

P099

ANTI-PD1-INDUCED PSORIASIS. A CASE SERIES
Bonigen J., Raynaud C., Hureaux J., Kramkimel N., Blom A., Jeudy G., Breton A.-L., Hubiche T., Bedane C., Legoupil D., Pham-Lédard A., Pérol M., Gérard E., Combemale P., Sigal M.-L., Mahé E.* et Groupe de Recherche sur le Psoriasis of the SFD, Groupe Cancérologie Cutanée of the SFD, GEM Resopso, Apsoderm, CEDEF, Groupe Français de Pneumo-Cancérologie (Argenteuil, France)

P100

TISSUE-RESIDENT MEMORY T CELLS IN THE RECURRENCE OF PSORIASIS
Shen Z.*, Chen L., Chen Y., Yang J. (Chongqing, China)

P101

MODULATION OF FOXP3 BY LEPTIN VIA STAT3 SIGNAL IN PSORIASIS
Chen L.*, Yang J., Chen Y., Shen Z. (Chongqing, China)

P102

THE EXPRESSION OF INFLAMMATORY CYTOKINES ACCORDING TO PHENOTYPIC HETEROGENEITY OF PSORIASIS : PLAQUE AND GUTTATE
Yoon Y. H., Choe Y. B., Kang L. H., Paik S. Y., Park  C. J.* (Bucheon, Korea, Republic Of)

P103

PUTATIVE ROLES FOR ACTIVATING TRANSCRIPTION FACTOR 3 (ATF3) IN PATHOGENESIS OF PSORIASIS
Lee J.-H.*, Choi M.-R., Choi D.-K., Lee J.-H., Kim C.-D. (Daejeon, Korea, Republic Of)

P104

THE EFFECT OF CD147 ON CYTOKINE IL-22 MEDIATED CELLULAR BIOLOGICAL FUNCTION IN PSORIATIC KERATINOCYTES
Chen X., Zhang X.*, Zhang S., Su J., Jia X. et Hunan key Laboratory of Skin Cancer and Psoriasis, Xiangya Hospital, Central South University, Changsha, Hunan, China (Changsha City, Hunan Province, China)

P105

A STUDY OF THE BALANCE OF TH17 CELLS AND REGULATORY T CELLS IN PSORIASIS
Shin B. S.*, Kim M., Na C. H., Kim D. J. (Gwangju, Korea, Republic Of)

P106

ELEVATED MATRIX METALLOPROTEINASES 3 AND 9 LEVELS ARE ASSOCIATED WITH INFLAMMATORY IN PSORIASIS PATIENTS
Abbes A.*, Monia A.-E., Dalinda E. E., Amel M., zidi W., Berrima A., Aloui S., zayani Y., Feki M., Mokni M., Naziha K. (Tunis, Tunisia)

P107

SERUM AND TISSUE ZINC LEVELS IN PSORIASIS:  A META-ANALYSIS
Chen X.*, Chen W., Zhu W., He Y. (Changsha City, Hunan Province, China)

P108

KERATINOCYTES PROCESS AND PRESENT SELF-ANTIGEN AND ACTIVATE T CELLS
Hao J.*, Wang G. (Xi'an, China)

P109

EFFECT OF ENVIRONEMENTAL FACTORS ON PSORIASIS IN TUNISIAN PATIENTS
Alaoui F.*, youssef S., karray M., abdelhedi N., alkathiri M., jaber K., dhaoui R., doss N. (tunis, Tunisia)

P110

ALTERNATIVE KERATIN 17 EXPRESSION VARIATION IS INDUCED BY DIFFERENT DOSES OF NARROW-BAND ULTRAVIOLET B IN KERATINOCYTES VIA ERK1/2-DEPENDENT MECHANISM
Han C., Hao J.*, Wang G. (Xi'an, China)

P111

IN VITRO APPLICATIONS OF PSORIATIC SKIN SUBSTITUTES FOR DERMATOLOGICAL PURPOSES
Pouliot R.*, Gendreau I. (Québec, Canada)

P112

EVALUATION OF DETECTION GENE EXPRESSION TRANSCRIPTION FACTOR RORC IN PLAQUE PSORIASIS
Mansouri M.*, Mansouri P., Raz  A., Jadali Z. (Tehran, Iran, Islamic Republic Of)

P113

EPITHELIAL-MESENCHYMAL TRANSITION IN PSORIATIC EPIDERMAL KERATINOCYTES
Man X.*, Li W., Landeck  L., Chen X., Zheng M. (Hangzhou, China)

P114

ANALYSIS OF MAJOR ADVERSE CARDIOVASCULAR EVENTS IN THE PSORIASIS LONGITUDINAL ASSESSMENT AND REGISTRY STUDY (PSOLAR)
Bissonnette R.*, Gottlieb A. B., Kerdel F., Naldi L., Papp K., Calabro S., Langholff W., Fakharzadeh S., Goyal K. (Montreal, Canada)

P115

HEDGEHOG PATHWAY IN PSORIATIC KERATINOCYTES
Cao H.*, Li W., Landeck  L., Chen X., zheng M., Man X. (Hangzhou, China)

P116

DECIPHERING THE ROLE OF IL-36 IN PSORIASIS
Witte E.*, Doecke W.-D., Ramm M., Schmidt N., Jodl S., Volk H.-D., Sterry W., Wolk K., Sabat R. (Berlin, Germany)

P117

NEW TH-POPULATIONS PLAY AN IMPORTANT ROLE IN PSORIASIS PATHOGENESIS BY PRODUCING GM-CSF
Sabat R.*, Witte K., Witte E., Gonsior M., Volk H.-D., Wolk K. (Berlin, Germany)

P118

GENETIC AND IMMUNOHISTOCHEMICAL ANALYSIS OF PSORIASIS IN TUNISIAN FAMILIES: GENETIC AND PHENOTYPIC HETEROGENEITY
Bougacha N.*, Ammar R., Marrakchi S., Turki H., Smahi A., Ayadi H. (Sfax, Tunisia)

P119

INVESTIGATION OF CYTOKERATINS 6, 16, 17 AND FACTORS VASCULAR IN PSORIASIS AND GEOGRAPHIC TONGUE
Carneiro S.*, Picciani B. L. S., de Carla Santos V., Pedra Dias E. (Rio de Janeiro, Brazil)

P120

PSORIASIS TREATMENT WITH STANDARD OR PERSONALIZED BIOLOGICAL PRODUCTS PC2
Constantin C.*, Chiurciu V., Lucica S., Iuliana M., Ionel Victor P. (Voluntari, Ilfov County, Romania)

P121

IMPACT OF A PATIENT SUPPORT PROGRAM ON ADHERENCE AND HEALTHCARE COSTS IN PATIENTS WITH PSORIASIS AND PSORIATIC ARTHRITIS
Strober B.*, Skup M., Mittal M., Davis M., Sundaram M., Johnson S., Chao J. (Farmington, United States)

P122

EVALUATION OF THE ANNUAL COST OF PSORIASIS BY SYSTEMIC TREATMENT. EXPERIENCE HOSPITAL DERMATOLOGY DEPARTMENT OF TLEMCEN WEST ALGERIA.
Boudghene Stambouli O. B.*, Nassima C., Boumedienne  D. (Tlemcen, Algeria)

P123

PSORIASIS: A PUBLIC HEALTH PROBLEM IN ALGERIA
Boudghene Stambouli O. B.*, Boumedienne  D. (Tlemcen, Algeria)

P124

ACCESS TO MEDICINES,ITOLIZUMAB,BIOSIMILARS AND BIOCOPIES
Kumar A. S.*, kirit R. (hyderabad, India)

P125

COST-EFFECTIVENESS OF SECUKINUMAB COMPARED WITH USTEKINUMAB AND ETANERCEPT FOR THE TREATMENT OF MODERATE-TO-SEVERE PLAQUE PSORIASIS IN GREECE
Tzanetakos C.*, Kourlaba G., Hatzikou M., Antoniou C., Ioannides D., Lefaki I., Petridis A., Rigopoulos D., Roussaki-Schulze V., Sotiriadis D., Maniadakis N. (Athens, Greece)

P126

COSTS AND RESULTS OF CLIMATOTHERAPY FOR PSORIASIS
Harari M.* (Ein Bokek, Israel)

P127

PATIENT PREFERENCE ON PSORIASIS TREATMENT IN A PHILIPPINE TERTIARY HOSPITAL: A CONJOINT ANALYSIS
Guevara B. E. K.*, Gonzales N., Visitacion L. (Davao, Philippines)

P128

MEASURING WILLINGNESS-TO-PAY AND HEALTH-RELATED QUALITY OF LIFE IN PATIENTS WITH PSORIASIS IN CHINA
Xiao Y.*, Su J., Guan X., Shi X., Chen X. (Changsha city, Hunan Province, China)

P129

PSORIASIS: SELF-IMAGE AND QUALITY OF LIFE GREATLY ALTERED: ABOUT A UNIT STUDY PSYCHOLOGY IN THE WEST UNIVERSITY HOSPITAL DERMATOLOGY DEPARTMENT TLEMCEN ALGERIA
Boudghene Stambouli O. B.*, Boumedienne D. (Tlemcen, Algeria)

P130

GLOBAL SURVEY INTO THE USE OF THERAPEUTIC PATIENT EDUCATION DURING PSORIASIS MANAGEMENT
Grine L.*, Lambert J., Paul C., Nast A. et Psoriasis International Network Scientific Committee (Ghent, Belgium)

P131

ADALIMUMAB FOR NAIL PSORIASIS: EFFICACY AND SAFETY FROM THE FIRST 26 WEEKS OF A PHASE-3, RANDOMIZED, PLACEBO-CONTROLLED TRIAL
Elewski B. E.*, Rich P. A., Okun M. M., Papp K., Baker C. S., Crowley J. J., Guillet G., Gu Y., Geng Z., Sundaram M., Williams D. A. (Birmingham, United States)

P132

ETANERCEPT: FIRST ALGERIAN EXPERIENCE IN PSORIASIS
Omar B. S.* (Tlemcen, Algeria)

P133

CODED UNANI FORMULATIONS (UNIM 401 SYSTEMICALLY AND UNIM 403 TOPICALLY) AND PUVASOL IN CHRONIC PLAQUE PSORIASIS: A NON-INFERIORITY RANDOMIZED CONTROLLED TRIAL 
Khanna N.*, Nazli T., Siddiqui K. M., Kalaivani M., Rahman R. (New Delhi, India)

P134

SUSTAINED EFFICACY WITH APREMILAST IN PATIENTS WITH NAIL AND SCALP PSORIASIS WHO CONTINUED ON APREMILAST OR SWITCHED FROM ETANERCEPT TREATMENT: 52-WEEK RESULTS FROM THE LIBERATE STUDY
Gooderham M.*, Zhang Z., Day R., Ferris L. (Peterborough, ON, Canada)

P135

EFFECT OF APREMILAST ON PATIENT-REPORTED OUTCOMES IN PATIENTS WITH MODERATE TO SEVERE PLAQUE PSORIASIS IN THE ESTEEM 1 TRIAL
Armstrong A. W.*, Griffiths C., Tencer T., Li S., Zhang F. (Los Angeles, CA, United States)

P136

SAFETY AND TOLERABILITY OF APREMILAST UP TO 182 WEEKS: POOLED ANALYSES FROM PHASE 3 CLINICAL TRIALS
Papp K.*, Sobell J., Shah K., Day R., Chen R., Paul C. (Waterloo, Canada)

P137

EFFICACY OF APREMILAST SUSTAINED THROUGH WEEK 52 IN PATIENTS WITH MODERATE TO SEVERE PSORIASIS WHO CONTINUED ON APREMILAST OR SWITCHED FROM ETANERCEPT TREATMENT: RESULTS FROM THE LIBERATE STUDY
Reich K.*, Papp K., van de Kerkhof P., Zhang Z., Nograles K., Soung J. (Hamburg, Germany)

P138

IXEKIZUMAB TREATMENT IMPROVES NAIL PSORIASIS IN PATIENTS WITH MODERATE-TO-SEVERE PSORIASIS:  RESULTS FROM THE RANDOMIZED AND CONTROLLED AS WELL AS OPEN-LABEL PHASES OF UNCOVER-3
Van de Kerkhof P.*, Guenther L., Gottlieb A., Sebastian M., Wu J., Foley P., Morita A., Goldblum O., Zhang L., Erickson J., Ball S., Rich P. (Nijmegan, Netherlands)

P139

CONTINUED TREATMENT WITH IXEKIZUMAB OVER 60 WEEKS PROVIDES SUSTAINED IMPROVEMENTS IN WORK PRODUCTIVITY AND ACTIVITY LEVELS: RESULTS FROM UNCOVER-2, A PHASE 3 TRIAL IN PATIENTS WITH MODERATE-TO-SEVERE PSORIASIS
Lynde C.*, McBride S., Ståhle M., Burge R., Lin C.-Y., Amato D. (Toronto, Canada)

P140

CONTINUED TREATMENT WITH IXEKIZUMAB OVER 60 WEEKS PROVIDES SUSTAINED IMPROVEMENTS IN ITCH AND OTHER PATIENT REPORTED OUTCOMES: RESULTS FROM UNCOVER-2, A PHASE 3 TRIAL
Strober B., Sofen H.*, Edson-Heredia E., Lin C.-Y., Goldblum O., Yosipovitch G. (Sylmar, United States)

P141

TREATMENT WITH IXEKIZUMAB OVER 60 WEEKS PROVIDES SUSTAINED IMPROVEMENTS IN HEALTH-RELATED QUALITY OF LIFE: RESULTS FROM UNCOVER-2, A RANDOMIZED PHASE 3 TRIAL
Warren R. B.*, Feldman S. R., Paul C., Strand V., Burge R., Lin C.-Y., Goldblum O. M., Reich K. (Manchester, United Kingdom)

P142

LONG-TERM EFFICACY AND SAFETY OF BRODALUMAB IN JAPANESE PATIENTS WITH PLAQUE PSORIASIS (PSORIASIS VULGARIS, PSORIATIC ARTHRITIS), PUSTULAR PSORIASIS (GENERALIZED) AND PSORIATIC ERYTHRODERMA: AN OPEN-LABEL EXTENSION STUDY.
Nakagawa H.*, Ootaki K. et KHK4827 Study Group (Tokyo, Japan)

P143

SAFETY OF TOFACITINIB, AN ORAL JANUS KINASE INHIBITOR: INTEGRATED DATA ANALYSIS FROM THE GLOBAL CHRONIC PLAQUE PSORIASIS CLINICAL TRIALS
Wolk R., Langley R.*, Cohen A., Foley P., Griffiths C., Lebwohl M., Leonardi C., Winthrop K., Proulx J., Rottinghaus S., Thompson J., Tatulych S., Mallbris L., Swanson R. (Halifax, Canada)

P144

IMPACT OF IXEKIZUMAB TREATMENT ON SCALP PSORIASIS:  RESULTS FROM THE PLACEBO-CONTROLLED INDUCTION PERIOD OF UNCOVER-3
Reich K.*, Leonardi C., Lebwohl M., Romiti R., Goldblum O., Zhang L., Shrom D., Dennehy E., Sofen H. (Hamburg, Germany)

P145

EARLY ONSET OF CLINICAL IMPROVEMENT WITH IXEKIZUMAB IN PATIENTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS.
Khatri S., Amir Y., Min M., Goldblum O., Solotkin K., Yang F., Ridenour T., Lebwohl M.* (New York, United States)

P146

EFFICACY OF IXEKIZUMAB IN PATIENTS WHO HAVE OR HAVE NOT RECEIVED PRIOR NONBIOLOGIC SYSTEMIC THERAPIES: A POOLED ANALYSIS OF THREE PHASE 3 TRIALS
Reich K.*, Menter A., Paul C., Valenzuela F., Puig L., Papp K., Shrom D., Gurbuz S., See K., McKean-Matthews M., Romiti R. (Hamburg, Germany)

P147

IXEKIZUMAB TREATMENT ENABLED PATIENTS WITH FACIAL PSORIASIS TO HAVE SIGNIFICANTLY BETTER HRQOL OUTCOMES BY WEEK 12: RESULTS FROM UNCOVER-3
Poulin Y.*, Sofen H., Burge R., Potts Bleakman A., Lin C.-Y., Mallbris L., Paul C. (Quebec, Canada)

P148

BASELINE DEMOGRAPHICS AND DISEASE CHARACTERISTICS OF LONG-TERM RESPONDERS TO ADALIMUMAB IN REVEAL
Yamauchi P.*, Maa J.-F., Valdecantos W. (Los Angeles, United States)

P149

A PROSPECTIVE, RANDOMIZED, DOUBLE BLINDED CLINICAL TRIAL COMPARING A MIXTURE OF HERBAL OILS WITH CALCIPOTRIOL AND VEHICLE IN MILD PLAQUE PSORIASIS
Mansouri P.*, Nahavandi A., Rohani-Nasab M. (Tehran, Iran, Islamic Republic Of)

P150

104-WEEK EFFICACY AND SAFETY PROFILE OF APREMILAST IN PATIENTS WITH PSORIATIC ARTHRITIS: RESULTS FROM A PHASE III, RANDOMIZED, CONTROLLED TRIAL AND OPEN-LABEL EXTENSION (PALACE 1)
Kavanaugh A. F., Gladman D., Gomez-Reino J., Hall S., Lespessailles E.*, Mease P., Schett G., Shah K., Hu A., Wollenhaupt J. (Orléans, France)

P151

IXEKIZUMAB IMPACT ON THE SKIN-RELATED RELATIONSHIP PROBLEMS OF PATIENTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS: INTEGRATED RESULTS FROM THREE PHASE 3 TRIALS (UNCOVER-1, -2, -3)
Warren R. B.*, Cather J., Ohtsuki M., Potts Bleakman A., Burge R., Zhu B., Reich K. (Manchester, United Kingdom)

P152

PREDICTORS OF RESPONSE TO TOFACITINIB OR ETANERCEPT IN A PHASE 3 RANDOMISED, NON-INFERIORITY STUDY IN PATIENTS WITH MODERATE TO SEVERE CHRONIC PLAQUE PSORIASIS
Lambert J., Strohal R., de la Cruz C., Thaçi D., Bachelez H.*, Iversen L., Rottinghaus S., Tallman A., Tan H., Berstein G. (Paris, France)

P153

EFFICACY AND SAFETY OF IXEKIZUMAB COMPARED TO ETANERCEPT OR PLACEBO TREATMENT OF PATIENTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS AND PALMOPLANTAR INVOLVEMENT OVER A 60-WEEK DOSING PERIOD: RESULTS FROM UNCOVER-3, A PHASE 3 TRIAL
Warren R. B.*, Morita A., Menter A., Callis Duffin K., Langley R., Amato D., Dennehy E. B., Kerr L. N., Shrom D., Reich K. (Manchester, United Kingdom)

P154

IXEKIZUMAB TREATMENT IMPROVES SKIN-RELATED SEXUAL DIFFICULTIES IN PATIENTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS: INTEGRATED RESULTS FROM THREE PHASE 3 TRIALS (UNCOVER-1, -2 AND -3)
Guenther L. C.*, Foley P., Cather J., Potts Bleakman A., Burge R., Zhu B., van de Kerkhof P. (London, Canada)

P155

CODED UNANI FORMULATIONS (UNIM 401 SYSTEMICALLY AND UNIM 403 TOPICALLY) AND PUVASOL IN CHRONIC PLAQUE PSORIASIS: NON-INFERIORITY RANDOMIZED CONTROLLED CLINICAL TRIAL
KHANNA N.*, NAZLI T., SIDDIQUI K. M., KALAIVANI M., RAHMAN R. U. (NEW DELHI, India)

P156

STUDY ON THE EFFECT OF METHOTREXATE ON ACTIVATION OF TREG CELLS IN PSORIASIS AND MICE MODEL
Chen X., Zhang H., Kuang Y.* (Changsha City, Hunan Province, China)

P157

EFFICACY OF TOFACITINIB FOR THE TREATMENT OF NAIL PSORIASIS: TWO 52-WEEK PHASE 3 STUDIES IN PATIENTS WITH MODERATE TO SEVERE PLAQUE PSORIASIS
Kaur M.*, Merola J., Tatulych S., Mamolo C., Lan S. (Collegeville, United States)

P158

T CELL-MEDIATED IMMUNE RESPONSE TO PNEUMOCOCCUS AND TETANUS TOXOID VACCINES IN PATIENTS WITH MODERATE TO SEVERE PSORIASIS FOLLOWING LONG-TERM ORAL TOFACITINIB TREATMENT
Winthrop K., Korman N., Abramovits W., Valdez H., Rottinghaus S., Tan H., Gardner A., Mukwaya G., Kaur M.* (Collegeville, United States)

P159

DETERMINING THE INDIRUBIN DOSAGE TO TREAT PSORIASIS VULGARIS EFFECTIVELY AND SAFELY USING TOPICALLY APPLIED LINDIOIL OINTMENT: A RANDOMIZED AND DOUBLE-BLIND TRIAL
Lin Y.-K.*, Hui C.-Y. R., Huang Y.-H. (Taipei, Taiwan, Province of China)

P160

EPIDEMIOLOGY OF PSORIASIS
Eltaweel A.* (cairo, Egypt)

P161

CLINICAL FEATURE OF PSORIASIS PATIENTS  IN KOREA
Lee K.*, Yang J., Yoo J., Chang G. T. (Seoul, Korea, Republic Of)

P162

PSORIASIS IN PANAMA: THE FIRST DESCRIPTIVE STUDY IN PANAMA'S LARGEST TERTIARY REFERRAL HOSPITAL (PSOPAN)
Isaza Gonzalez G.*, Samudio Naar O., Rizo Bekerman J. (Panama City, Panama)

P163

CHARACTERISTICS AND TREATMENT PATTERN COMPARISONS OF A REAL-WORLD COHORT OF PATIENTS ELIGIBLE AND INELIGIBLE FOR MODERATE-TO-SEVERE PSORIASIS CLINICAL TRIALS
Wu J.*, Araujo A., Nordstrom B., Goldblum O., Solotkin K., Lin C.-Y., Johnston J., Kistler K., Fraeman K., Malatestinic W. (Los Angeles, United States)

P164

PATIENTS WITH PSORIASIS AND THE INTERNET: PROFILE OF THE POPULATION CONSULTING WEBSITES, AND EVALUATION OF THE WEBSITES
Amy De La Breteque M., Sigal M.-L., Maccari F., Barthélémy H., Esteve E., Girard C., Maillard H., Avenel-Audran M., Perrot J.-L., Modiano P., Quikes-Tsimaratos N., Parier J., Begon E., Pallure V., Becherel P.-A., Chaby G., Beauchet A., Mahé E.* et GEM resopso (Argenteuil, France)

P165

STUDY ON SMOKING AND ALCOHOL CONSUMPTION AMONG KOREAN PSORIASIS PATIENTS
Lee K.*, Yang J., Yoo J., Chang G. T., Yang I. J. (Seoul, Korea, Republic Of)

P166

PSORIASIS TREATMENT IN A REFERRAL CENTRE IN MÉXICO
Quiroz Vergara J. C.*, Morales Sánchez M. A., Castillo Rojas G., López-Vidal Y., Peralta Pedrero M. L., Jurado Santa Cruz  F., Orozco Anahuati  A. P., Samuel P. D. L. R. (Ciudad de México, Mexico)

P167

A QUESTIONNAIRE BASED STUDY ON THE PERCEPTION OF USE OF BIOLOGICS IN THE TREATMENT OF MODERATE TO SEVERE PSORIASIS AMONG DERMATOLOGISTS IN INDIA
Hs S.*, Kumar S., Kumar V., Shukla R., Paul D. (Bangalore, India)

P168

FAMILY HISTORY OF PSORIASIS AND AGE OF ONSET OF THE DISEASE IN TUNISIAN CASES
Karray M.*, Youssef S., Alkathiri M., Alaoui F., Abdelhedi N., Jaber K., Dhaoui R., Doss N. (Tunis, Tunisia)

P169

PSORIASIS EPIDEMIOLOGY IN A TERTIARY REFERRAL CENTRE IN SOUTH INDIA
Kirit R.*, parthasardhi A. (hyderabad, India)

P170

CLINICAL EFFICACY OF FACIAL PSORIASIS WITH TOPICAL TACROLIMUS OINTMENT
Zou X.*, Qiu M. (Beijing, China)

P171

LINEAR PSORIASIS. A CROSS-SECTIONAL STUDY OF 30 CASES
Mahé E.*, Boralevi F., Lenormand C., Bursztejn A.-C., Estève E., Phan A., Bourrat E., Lacour J.-P., Richard M.-A., Acher A., Beneton N., Descamps V., Bodemer C., Lagaude M., Sigal M.-L., Jullien D. et Gr Pso of the SFD, SFDP, GEM Resopso, Cedef, and Apsoderm (Argenteuil, France)

P172

ANNULAR PUSTULAR PSORIASIS - DIAGNOSTIC CHALLENGE
Owczarczyk-Saczonek A.*, Placek W. (Olsztyn, Poland)

P173
EVALUATION OF THE CLINICAL CHARACTERISTICS OF PRURITUS IN PATIENTS WITH PSORIASIS USING THE JAPANESE VERSION OF THE 5-D ITCH SCALE

Ishiuji Y.*, Umezawa Y., Asahina A., Yanaba K., Ebata T., Nakagawa H. (Tokyo, Japan)

P174

ITOLIZUMAB, ANTI CD-6 BIOLOGIC, IN SEVERE PSORIASIS – A CASE STUDY
Trasi S.* (Mumbai, India)

P175

LUNG AFFECTIONS IN PSORIASIS – ARE THEY RELEVANT?
Moreira A., Sticherling M.* (Erlangen, Germany)

P176

CLINICAL CHARACTERIZATION AND COURSE OF GUTTATE PSORIASIS
Ferran M.*, Pujol R. M. (Barcelona, Spain)

P177

INTERMITTENT HIGH DOSE AND CONTINUOUS LOW DOSE AZATHIOPRINE FOR THE TREATMENT OF PSORIASIS
Gupta R.* (New Dellhi, India)

P178

EFFECTIVENESS AND SAFETY WITH BIOLOGIC AGENTS IN PATIENTS WITH PSORIASIS
Arroyo Jaramillo S. E.*, Serrano L., ferreira hermosillo A. (durango, Mexico)

P179

CLINICAL OUTCOME OF A NOVEL PROMISING ANTI CD-6 BIOLOGIC ITOLIZUMAB, IN 21 PATIENTS WITH PSORIASIS AND CO MORBID CONDITIONS
Singh V.* (Jhajjhar, India)

P180

PSORIASIS AND METABOLIC SYNDROME; PRELIMINARY STUDY: EXPERIENCE OF DEPARTMENT OF DERMATOLOGY OF TLEMCEN (WEST ALGERIA). ABOUT OF 207 CASES
Omar B. S.* (Tlemcen, Algeria)

P181

5-YEAR USE OF USTEKINUMAB FOR PSORIASIS: THE EXPERIENCE OF A SINGLE CENTER
Vergou T.*, MOUSTOU A. E., ANTONIOU C. (ATHENS, Greece)

P182

ANTI-PSORIATIC POTENTIAL AND SAFETY OF A NOVEL POLYHERBAL FORMULATION
Shraibom N., Madaan A., Verma R., Singh P., Dobhal S., Kar R., Chaudhary A., Mishra G., Awasthi A., Mookkan J., Singh A. T.*, Jaggi M. (Uttar Pradesh, India)

P183

TREATMENT RESPONSE TO BIOLOGICS AGENTS IN PSORIATIC PATIENTS WITH OR NOT PSORIATIC ARTHRITIS
Masouri S.*, Moustou A.-E., Papoutsaki M., Stefanaki I., Sachlas A., Vergou T., Antoniou C. (ATHENS, Greece)

P184

INFLIXIMAB: ADVERSE EVENTS AS REASON FOR TREATMENT DISCONTINUATION
Moustou A.-E.*,  Papoutsaki M., Vergou T., Masouri S.,  Sachlas A., Antoniou C. (ATHENS, Greece)

P185

ERYTHRODERMIC PSORIASIS IMPROVED BY USTEKINUMAB : A REPORT OF TWO CASES
Park Y. L.*, Whang K. U., Lee J. S., Lee S. H., Jung  G. H., An J. M. (Bucheon-Si, Gyeonggi-Do, Korea, Republic Of)

P186

EFFECTS OF HUMAN MESENCHYMAL STEM CELLS TRANSDUCED WITH SUPEROXIDE DISMUTASE ON IMIQUIMOD-INDUCED PSORIASIS-LIKE SKIN INFLAMMATION IN MICE
Kim T. Y.*, Sah S. K. (Seoul, Korea, Republic Of)

P187

A DOSE-RESPONSE MODEL-BASED META-ANALYSIS TO COMPARE TOFACITINIB TO OTHER PSORIASIS TREATMENTS
Strober B., Checchio T., Gupta P., Mandema J., Wolk R., Valdez H., Tan H., Puig L., Krishnaswami S., Tallman A.*, Kaur M., Ito K. (New York, United States)

P188

PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY AND RENAL FANCONI SYNDROME ASSOCIATED WITH FUMARIC ACID ESTERS TREATMENT FOR PSORIASIS
Balak D. M.*, Neumann H. M., Thio H. B. (Rotterdam, Netherlands)

P189

EVALUATION OF CLINICAL RESPONSE WITH REDUCED MAINTENANCE DOSE OF SECUKINUMAB 150MG
De la Cruz C.*, Armijo D., Tossi C., Del Rio T. (Santiago, Chile)

P190

NEW-ONSET PSORIASIS INDUCED BY RITUXIMAB THERAPY
González Lara L.*, Palacio Aller L., Vázquez Osorio I., Usero  T., González Delgado S., Rodríguez Díaz E. (Gijón, Spain)

P191

A TREATMENT CHALLENGE – SEVERE PSORIASIS, IGA NEPHROPATHY AND SARCOIDOSIS
Ozanic Bulic S.*, Horvatic I., Tekavec Trkanjec J., Galesic Ljubanovic  D., Perica A. (Zagreb, Croatia)

P192

PREDICTORS OF LONG-TERM DRUG SURVIVAL FOR INFLIXIMAB IN PSORIASIS
Magis Q., Jullien D., Gaudy C., Baumstark K., Viguier M., Bachelez H., Guibal F., Delaporte E., Karimova E., Montaudié H., Boyé T., Aubin F., Beylot-Barry M., Richard M.-A.* et Groupe Psoriasis de la Société Française de Dermatologie (Marseille, France)

P193

IMPROVEMENT OF SYSTEMIC/VASCULAR INFLAMMATION USING USTEKINUMAB IN PSORIASIS PATIENTS: MEASURED BY 18FDG POSITRON EMISSION TOMOGRAPHY-COMPUTED TOMOGRAPHY
Lee W.-K., Park C.-J., Ko H.-C., Kim M.-B., Kim B.-S.* (Busan, Korea, Republic Of)

P194

CUSHING’S SYNDROME INDUCED BY MINIMAL DAILY APPLICATION OF A POTENT TOPICAL STEROID
Coo E. R. L.*, Bunagan M. K. (Davao City, Philippines)

P195

BIOSIMILARS IN PSORIASIS:  CLINICAL PRACTICE AND REGULATORY PERSPECTIVES IN LATIN AMERICA
De la Cruz C.*, Carvalho A., Leon-Dorantes  G., Londoño Garcia A., Gonzalez C., Maskin M., Podoswa  N., Redfern J., Valenzuela F., Van Der Walt J., Romiti R. (Santiago , Chile)

P196

TREATMENT OF PSORIASIS WITH NARROW-BAND UVB PHOTOTHERAPY
Astsaturov H.* (Lviv, Ukraine)

P197

PATIENTS WITH PYODERMA GANGRENOSUM AND NEUTROPHILIC PSORIASIS RESPOND TO SELECTIVE DEPLETION OF MYELOID LINEAGE LEUCOCYTES BY ADSORPTIVE APHERESIS
Saniabadi A.*, Shiobara N. (Takasaki, Japan)

P198

THE HERBAL MEDICINE FORMULA DANG-GUI-LIU-HUANG-TANG AMELIORATES IMIQUIMOD-INDUCED PSORIASIS-LIKE SKIN LESION BY INHIBITING INFLAMMATORY CYTOKINE PRODUCTION
Chang G. T.*, Lee K., Yang I. J., Shin H. M. (seoul, Korea, Republic Of)

P199

USTEKINUMAB IN THE TREATMENT OF  GENERALISED PUSTULAR PSORIASIS: A CASE REPORT
Engin B.*, Serdaroğlu S., Oba Ç., Kutlubay Z. (Istanbul, Turkey)

P200

USTEKINUMAB IN THE TREATMENT OF  PSORIASIS UNRESPONSIVE TO OTHER BIOLOGICAL AGENTS : A CASE REPORT
Serdaroğlu S., Engin B.*, Oba Ç., Kutlubay Z., Tüzün Y. (Istanbul, Turkey)

P201

THE ANALYSIS OF THE EFFICACY OF BIOLOGIC THERAPY FOR SEVERE PSORIASIS IN INTERMITTENT COURSES WITH THE SAME DRUG.
Klujszo E.*, Cyran-Stemplewska S., Parcheta P., Słowik-Rylska M. (Kielce, Poland)

P202

DRUG SURVIVAL OF BIOLOGICS IN PATIENTS WITH PSORIASIS: ANALYSIS OF THE SLOVENE REGISTRY DATA (2005-2015)
Lunder T.*, Marko P., Tlaker Zunter V., Koser Kolar N., Kralj B., Kecelj Leskovec N. (Ljubljana, Slovenia)

P203

RAPID RESPONSE TO INFLIXIMAB IN THE TREATMENT OF CHRONIC PLAQUE PSORIASIS: A CASE REPORT
Tüzün Y.*, Engin B., Uzun A. (Istanbul, Turkey) 

P204

INTERVENTIONS FOR NAIL PSORIASIS
Busard C.*, Pasch M., Oudshoorn S., de Vries A. C., Hooft L., Spuls P. (Amsterdam, Netherlands)

P205

THERAPEUTIC EVALUATION IN PSORIATIC PATIENTS: 467 CASES
Abdelhedi N.*, youssef S., alaoui F., karray M., alkathiri M., jaber K., dhaoui R., doss N. (tunis, Tunisia)

P206

PARADOXICAL REACTIONS OF ANTI-TUMOUR NECROSIS FACTOR IN INFLAMMATORY DISEASES.
Karray M.*, Youssef S., Alkhathiri M., Fatima A., Nour A., Jaber K., Dhaoui R., Doss N. (Tunis, Tunisia)

P207

TREATMENT OF ERYTHRODERMIC PSORIASIS WITH BIOLOGICAL THERAPIES IN TWO CASES
Sahel H.*, Otsmane F., Bouadjar B. (Algiers, Algeria)

P208

PHOTOTHERAPY-INDUCED ERYTHEMA IN A PATIENT WITH PSORIASIS AND OBESITY TREATED WITH NARROWBAND UVB PHOTOTHERAPY
Sahel H.*, Otsmane F., Bouadjar B. (Alger, Algeria)

P209

MULTIPLE MYELOMA IN A PATIENT WITH SEVERE PSORIASIS UNDER INFLIXIMAB
Sahel H.*, Saidi A., Ait belkacem K., Benmohand C., Otsmane F., Bouadjar B. (Alger, Algeria)

P210

PEGYLATED INTERFERON ALPHA AND RIBAVIRIN: TRIGGERING FACTORS OF PSORIASIS
Karray M.*, Youssef S., Ghanem M., Abdelhedi N., Alaoui F., Jaber K., Dhaoui R., Abdelli N., Doss N. (Tunis, Tunisia)

P211

ANTI-DRUG ANTIBODIES AND THE ANTI TNF-Ɑ THERAPY FOR SEVERE PSORIASIS: A SURVEY ON ELEVEN PATIENTS
Salavastru C. M.*, Sendrea A. M., Cretu S., Tiplica G. S. (Bucharest, Romania)

P212

THERAPEUTIC DRUG MONITORING OF USTEKINUMAB IN PSORIATIC PATIENTS: SENSE OR NONSENSE?
De Keyser E.*, Busard C., Coussens E., van den Reek J., Botti E., Meuleman L., Van De Kerckhove M., Boonen H., Antonio C., de Jong E., Lambert J., Spuls P. (Ghent, Belgium)

P213

SECONDARY SYPHILIS DURING BIOLOGIC TREATMENT – ANOTHER INFECTION TO MONITOR?
Uslu U., Heppt F., Sticherling M.* (Erlangen, Germany)

P214

PSORIASIS EXACERBATED BY LEDIPASVIR/SOFOSBUVIR FOR HEPATITIS C
Heppt F., Sticherling M.* (Erlangen, Germany)

P215

PARADOXICAL PSORIASIS INDUCED BY ANTI-TNF ALPHA AGENTS: TEN CASES REPORT WITH TREATMENT OPTIONS
Vorcakova K.*, Pecova T., Pec J. (Martin, Slovakia)

P216

CARD14 alterations in Tunisian patients with psoriasis and further characterization in European cohorts.
Ammar M.*, Jordan  C., Cao L., Lim E., souissi bouchlaka C., zaraa I., Anbunathan H., mokni M., doss N., Guttman-Yassky E., el gaaied  A., menter A., Bowcock A. (Tunis, Tunisia)

P217

VEGF–A plays an essential role in itchy psoriasis by promoting epidermal hyperinnervation in imiquimod-induced psoriasiform model
Wong L.-S.*, Otsuka A., Kabashima K. (Kaohsiung, Taiwan, Province of China)

P218

CF101 via A3AR Activation inhibits IL-17 and IL-23 in Human Keratinocytes
Cohen S.*, Barer F., Fishman P. (Petach Tikva, Israel)

P219

Comparable Efficacy but longer Drug Survival of Biologics vs conventional systemic Therapy – an Analysis of the Swiss Registry for Psoriasis
Maul J.-T.*, Kolios A., Djamei V., Meier B., Czernielweski J., Yawalkar N., Laffitte E., Spehr C., Anliker M., Streit M., Augustin M., Rustenbach S., Conrad C., Hafner J., Boehncke W.-H., Borradori L., Gilliet M., Itin P., French L., Haeusermann P., Navarini A. (Zürich, Switzerland)

P220

Does tumour necrosis factor inhibitor therapy affect the incidence of myocardial infarction in patients with psoriasis?
Shaaban D., Al-Mutairi N.* (Kuwaitf city, Kuwait)

P221

Reduced Incidence of Dementia in Patients with Psoriasis: A National Population-Based Matched-Cohort Study
Chiu H.-Y.*, Chang W.-L., Huang W.-F., Tsai Y.-W., Lin S.-J., Tsai T.-F. (Hsinchu, Taiwan, Province of China)

P222

GP2015, a proposed etanercept biosimilar, has equivalent efficacy, safety and immunogenicity to etanercept originator product in patients with chronic plaque-type psoriasis: 12 week results from the phase 3 EGALITY study
Griffiths C. E., Thaci D.*, Gerdes S., Pulka G., Kingo K., Weglowska J., Reich K., Afonso M. (Lubeck, Germany)

P223

TIME COURSE OF IXEKIZUMAB DRUG LEVELS AND THE RELATIONSHIP AT WEEK 60 TO EFFICACY IN PATIENTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS (UNCOVER-3)
Reich K.*, Choi S. L., Jackson K., Mallbris L., Blauvelt A. (Hamburg, Germany)

P224

Secukinumab Exhibits Low Immunogenicity During 3 Years of Treatment in Subjects with Moderate to Severe Plaque Psoriasis
Reich K.*, Blauvelt A., Armstrong A. W., Warren R. B., Messina I., Ren M., Liang E., Spindeldreher S., Fox T., Papavassilis C., Bruin G. (Hamburg, Germany) 

 

 

PSORIATIC ARTHRITIS AND PRIMARY SCLEROSING CHOLANGITIS: ROLE OF METHOTREXATE?